JP Morgan Chase
LBRX

JP Morgan Chase’s LB Pharmaceuticals LBRX Stock Holding History

JP Morgan Chase’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.9M Buy
1,497,293
+69,725
+5% +$2.05M ﹤0.01% 1497
2026
Q1 		$33.2M Sell
1,427,568
-183,914
-11% -$4.24M ﹤0.01% 1661
2025
Q4 		$35.9M Buy
1,611,482
+578,879
+56% +$10.1M ﹤0.01% 1589
2025
Q3 		$16.3M Buy
+1,032,603
New +$16.4M ﹤0.01% 2266

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's LBRX Position: Q2 2026 in Review

JP Morgan Chase increased its LB Pharmaceuticals (LBRX) stake by 4.9% in Q2 2026, buying an estimated $2.05M and bringing the position to 1,497,293 shares worth $48.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

JP Morgan Chase first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • JP Morgan Chase held 1,497,293 shares of LB Pharmaceuticals worth $48.9M as of Q2 2026.
  • JP Morgan Chase bought 69,725 LB Pharmaceuticals shares in Q2 2026, an estimated $2.05M.
  • LB Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1497 holding.
  • JP Morgan Chase first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.